🎥 #OAOnTheGO | #ESMO26 Madrid
@OncoAlert
Personalized cancer vaccination is moving from concept to clinically meaningful signal.
INTerpath-001 is positive.
Dr. @MarioBalsaMD discusses pembrolizumab + personalized mRNA vaccine V940 in resected #Melanoma.
📊 2-year RFS: 82% vs 60%
HR 0.58
📊 DMFS: 88.5% vs 80.2%
HR 0.62
🎯 Why this matters: this is not simply another adjuvant immunotherapy study. It is a proof-of-concept that a patient-specific neoantigen vaccine can add meaningful disease-control benefit to PD-1 blockade.
For me, the next questions are even more important:
🧬 Who benefits most?
⏳ Will this translate into an OS advantage?
🔄 How should it be positioned relative to neoadjuvant immunotherapy?
🎯 Can biomarkers identify the patients who truly need this degree of personalization?
Excellent discussion by @MarioBalsaMD, building on important work from @ProfGLongMIA @jasonlukemd and the INTerpath-001 investigators.
🎬 Watch the latest #OAOnTheGO from @OncoAlert.
@DrBetofMDPhD @cdanicas @UOzkerim @DrMirallas @DrYukselUrun @GaiaGriguolo @JankovicK @ElisaAgostinett @to_be_elizabeth @nataliagandur
#OncoAlert #ESMO26 #Melanoma #mRNA #CancerVaccines #Immunotherapy #PrecisionOncology
52 views · 3 likes · 0 reposts · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid INTerpath-001 is positive! 🔬 @ProfGLongMIA @jasonlukemd Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma. 📊 2-year RFS: 82% vs 60% (HR 0.58) 📊 DMFS: 88.5% vs 80.2% (HR 0.62) Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy? 🎬 Watch now! #Melanoma #OncoAlert @DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein在 X 查看被引用的帖子
Source: Dra. María Natalia Gandur Quiroga · x.com